PPIG and rheumatoid arthritis: This is also further supported by the administration of biologics designed to target IL-6 or IL-6 receptors, such as tocilizumab, ruxolitinib, or sarilumab, resulting in restored CYP function along with lower drug plasma concentrations compared to untreated RA patients (101–106).